With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

What is your first line treatment recommendation for metastatic NSCLC with Met Exon 14 skipping mutation?

• Frontline IO alone (PD-1 >50%) or chemo-IO (PD-1 <50%) with capmatinib upon progression
• Capmatinib frontline with chemo-IO upon progression
• Capmatinib frontline with crizotinib upon progression
• Crizotinib frontline with capmatinib upon progression
• Capmatinib frontline and IO upon progression
• Other